FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000718691> ?p ?o ?g. }

• W2000718691 endingPage "1099" @default.
• W2000718691 startingPage "S" @default.
• W2000718691 abstract "Background and aims: The CDC estimates that 75% of the U.S. CHC population is between 50 and 70 years of age. As this population ages, the increasing rates of significant comorbidities including end stage liver disease will make CHC management more challenging. Drug-drug interactions from medications used to treat these comorbidities may also contraindicate or complicate the use of cytochrome P-450 metabolized protease inhibitors commonly used in anti-HCV regimens. The purpose of this study is to measure the rates of comorbidities and medications that may create barriers towards initiating anti-HCV regimens in a large U.S. CHC cohort. Methods: This was a retrospective database study of a large U.S. cohort of insured patients with CHC from 1/1/2009 to 6/30/2014. Patients with CHC were identified through ICD-9 coding. A total of 80,112 patients were analyzed: 76,115 with commercial and 3,997 with Medicaid insurance. Results: Two-thirds (66%) of our CHC population were aged between 50 and 70 years, 61% were male, and 11% were women of child-bearing age. Nearly 70% of patients had at least one significant comorbidity such as hypertension (49%), diabetes (22%), coronary artery disease (1.8%), HIV (4%), asthma or COPD (16%), chronic kidney disease (2%), and depression (14%). In addition, nearly one-third of patients (30%) had evidence for end stage liver disease with ascites, hepatic encephalopathy, or esophageal varices. Across the entire study period, the median number of first-time filled prescriptions for any medication per year was 3.5 (IQR, 1 to 8). Patients with comorbidities had a significantly higher median number of first-time filled prescriptions per year as compared to those without comorbidities (median 5 (IQR, 2 to 11) prescriptions per year with comorbidities versus median 1.5 (IQR, 0.5 to 3.5) prescriptions per year without comorbidities. Most commonly prescribed P-450 metabolized medications were HMG-CoA reductase inhibitors (13%), anxiolytics (18%), antibiotics (21%), and calcium channel blockers (14%). In addition, there were significantly more prescriptions for P-450 metabolized medications in patients with comorbidities (67%) compared to those without comorbidities (41%) (Figure 1). Conclusions: In this analysis of a large U.S. cohort of CHC patients, the majority (70%) of patients had at least one comorbid diagnosis of hypertension, diabetes, coronary artery disease, COPD, chronic kidney disease, or depression. In this population, approximately 67% also had at least one prescription for a P-450 metabolized medication that may pose significant drug-drug interactions with some of the anti-HCV protease inhibitors. Therefore, there may be significant barriers to treatments with current and upcoming antiHCV regimens in a significant proportion of patients with CHC." @default.
• W2000718691 created "2016-06-24" @default.
• W2000718691 creator A5011313939 @default.
• W2000718691 creator A5038740509 @default.
• W2000718691 creator A5040981505 @default.
• W2000718691 creator A5056240498 @default.
• W2000718691 date "2015-04-01" @default.
• W2000718691 modified "2023-09-25" @default.
• W2000718691 title "Tu1058 The Majority of Patients With Chronic Hepatitis C (CHC) in the US Have Significant Comorbidities and Polypharmacy" @default.
• W2000718691 doi "https://doi.org/10.1016/s0016-5085(15)33746-x" @default.
• W2000718691 hasPublicationYear "2015" @default.
• W2000718691 type Work @default.
• W2000718691 sameAs 2000718691 @default.
• W2000718691 citedByCount "0" @default.
• W2000718691 crossrefType "journal-article" @default.
• W2000718691 hasAuthorship W2000718691A5011313939 @default.
• W2000718691 hasAuthorship W2000718691A5038740509 @default.
• W2000718691 hasAuthorship W2000718691A5040981505 @default.
• W2000718691 hasAuthorship W2000718691A5056240498 @default.
• W2000718691 hasConcept C126322002 @default.
• W2000718691 hasConcept C159047783 @default.
• W2000718691 hasConcept C2522874641 @default.
• W2000718691 hasConcept C2776455275 @default.
• W2000718691 hasConcept C3020491458 @default.
• W2000718691 hasConcept C36434225 @default.
• W2000718691 hasConcept C71924100 @default.
• W2000718691 hasConcept C90924648 @default.
• W2000718691 hasConceptScore W2000718691C126322002 @default.
• W2000718691 hasConceptScore W2000718691C159047783 @default.
• W2000718691 hasConceptScore W2000718691C2522874641 @default.
• W2000718691 hasConceptScore W2000718691C2776455275 @default.
• W2000718691 hasConceptScore W2000718691C3020491458 @default.
• W2000718691 hasConceptScore W2000718691C36434225 @default.
• W2000718691 hasConceptScore W2000718691C71924100 @default.
• W2000718691 hasConceptScore W2000718691C90924648 @default.
• W2000718691 hasIssue "4" @default.
• W2000718691 hasLocation W20007186911 @default.
• W2000718691 hasOpenAccess W2000718691 @default.
• W2000718691 hasPrimaryLocation W20007186911 @default.
• W2000718691 hasRelatedWork W1572298971 @default.
• W2000718691 hasRelatedWork W2370383793 @default.
• W2000718691 hasRelatedWork W2418726410 @default.
• W2000718691 hasRelatedWork W2418867336 @default.
• W2000718691 hasRelatedWork W2619315573 @default.
• W2000718691 hasRelatedWork W3047213975 @default.
• W2000718691 hasRelatedWork W3207911508 @default.
• W2000718691 hasRelatedWork W4210823218 @default.
• W2000718691 hasRelatedWork W4238335663 @default.
• W2000718691 hasRelatedWork W776934392 @default.
• W2000718691 hasVolume "148" @default.
• W2000718691 isParatext "false" @default.
• W2000718691 isRetracted "false" @default.
• W2000718691 magId "2000718691" @default.
• W2000718691 workType "article" @default.